المؤلفون: Sanjay Kalra, Sarita Bajaj, Surendra Kumar Sharma, Gagan Priya, Manash P, Baruah, Debmalya Sanyal, Sambit Das, Tirthankar Chaudhury, Kalyan Kumar, Gangopadhyay, Ashok Kumar Das, Bipin Sethi, Vageesh Ayyar, Shehla Shaikh, Parag Shah, Sushil Jindal, Vaishali Deshmukh, Joel Dave, Aslam Amod, Ansumali Joshi, Sunil Pokharel, Faruque Pathan, Faria Afsana, Indrajit Prasad, Moosa Murad, Soebagijo Adi Soelistijo, Johanes Purwoto, Zanariah Hussein, Lee Chung Horn, Rakesh Sahay, Noel Somasundaram, Charles Antonypillai, Manilka Sumanathilaka, Uditha Bulugahapitiya

مصطلحات موضوعية: R Medicine (General), RC Internal medicine

الوصف: Aim To develop an evidence-based expert group opinion on the role of insulin motivation to overcome insulin distress during different stages of insulin therapy and to propose a practitioner’s toolkit for insulin motivation in the management of diabetes mellitus (DM). Background Insulin distress, an emotional response of the patient to the suggested use of insulin, acts as a major barrier to insulin therapy in the management of DM. Addressing patient-, physician- and drug-related factors is important to overcome insulin distress. Strengthening of communication between physicians and patients with diabetes and enhancing the patients' coping skills are prerequisites to create a sense of comfort with the use of insulin. Insulin motivation is key to achieving targeted goals in diabetes care. A group of endocrinologists came together at an international meeting held in India to develop tool kits that would aid a practitioner in implementing insulin motivation strategies at different stages of the journey through insulin therapy, including pre-initiation, initiation, titration and intensification. During the meeting, emphasis was placed on the challenges and limitations faced by both physicians and patients with diabetes during each stage of the journey through insulinization. Review Results After review of evidence and discussions, the expert group provided recommendations on strategies for improved insulin acceptance, empowering behavior change in patients with DM, approaches for motivating patients to initiate and maintain insulin therapy and best practices for insulin motivation at the pre-initiation, initiation, titration and intensification stages of insulin therapy. Conclusions In the management of DM, bringing in positive behavioral change by motivating the patient to improve treatment adherence helps overcome insulin distress and achieve treatment goals.

وصف الملف: text

العلاقة: http://repository.unair.ac.id/96990/1/a%20practitioner.pdfTest; http://repository.unair.ac.id/96990/2/A%20Practitioner%27s.pdfTest; http://repository.unair.ac.id/96990/3/A%20Practitioner%E2%80%99s%20Toolkit%20for%20Insulin%20Motivation%20in%20Adults%20with%20Type%201%20and%20Type%202%20Diabetes%20Mellitus_%20Evidence-Based%20Recommendations%20from%20an%20International%20Expert%20Panel_compressed.pdfTest; Sanjay Kalra and Sarita Bajaj and Surendra Kumar Sharma and Gagan Priya and Manash P and Baruah and Debmalya Sanyal and Sambit Das and Tirthankar Chaudhury and Kalyan Kumar and Gangopadhyay and Ashok Kumar Das and Bipin Sethi and Vageesh Ayyar and Shehla Shaikh and Parag Shah and Sushil Jindal and Vaishali Deshmukh and Joel Dave and Aslam Amod and Ansumali Joshi and Sunil Pokharel and Faruque Pathan and Faria Afsana and Indrajit Prasad and Moosa Murad and Soebagijo Adi Soelistijo and Johanes Purwoto and Zanariah Hussein and Lee Chung Horn and Rakesh Sahay and Noel Somasundaram and Charles Antonypillai and Manilka Sumanathilaka and Uditha Bulugahapitiya (2020) A Practitioner’s Toolkit for Insulin Motivation in Adults with Type 1 and Type 2 Diabetes Mellitus: Evidence-Based Recommendations from an International Expert Panel. Diabetes Therapy, 11 (8). pp. 585-606. ISSN 1869-6961

الإتاحة: https://doi.org/10.1007/s13300-020-00764-7Test
http://repository.unair.ac.id/96990Test/
http://repository.unair.ac.id/96990/1/a%20practitioner.pdfTest
http://repository.unair.ac.id/96990/2/A%20Practitioner%27s.pdfTest
http://repository.unair.ac.id/96990/3/A%20Practitioner%E2%80%99s%20Toolkit%20for%20Insulin%20Motivation%20in%20Adults%20with%20Type%201%20and%20Type%202%20Diabetes%20Mellitus_%20Evidence-Based%20Recommendations%20from%20an%20International%20Expert%20Panel_compressed.pdfTest

المؤلفون: Aslam Amod (7450015), John B Buse (5088452), Darren K McGuire (8712980), Thomas R Pieber (6493385), Rodica Pop-Busui (812593), Richard E Pratley (8616600), Bernard Zinman (796274), Marco Bo Hansen (7450023), Ting Jia (496916), Thomas Mark (447251), Neil R Poulter (8694739)

مصطلحات موضوعية: Cardiology, Endocrinology, Surgery, Nutrition and Dietetics not elsewhere classified, Cardiovascular, chronic renal failure, CVOT, diabetic kidney disease, type 2 diabetes mellitus, insulin analogues

الوصف: Supplemental material, sj-pdf-1-dvr-10.1177_1479164120970933 for Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12) by Aslam Amod, John B Buse, Darren K McGuire, Thomas R Pieber, Rodica Pop-Busui, Richard E Pratley, Bernard Zinman, Marco Bo Hansen, Ting Jia, Thomas Mark and Neil R Poulter in Diabetes & Vascular Disease Research

العلاقة: https://figshare.com/articles/journal_contribution/sj-pdf-1-dvr-10_1177_1479164120970933_Supplemental_material_for_Risk_factors_for_kidney_disorders_in_patients_with_type_2_diabetes_at_high_cardiovascular_risk_An_exploratory_analysis_DEVOTE_12_/14526658Test

الإتاحة: https://doi.org/10.25384/sage.14526658.v1Test

المؤلفون: Mohamed Hassanein, Mousa A. J. Akbar, Mostafa Al-shamiri, Ashraf Amir, Aslam Amod, Richard Chudleigh, Tarik Elhadd, Hussien Heshmat, Mahdi Jibani, Yousef M. Al Saleh

المصدر: Diabetes Therapy. 13:1253-1280

مصطلحات موضوعية: Endocrinology, Diabetes and Metabolism, Internal Medicine

الوصف: Cardiovascular disease (CVD) is a leading cause of death globally, driven by the high rates of risk factors, such as diabetes and hypertension. As the prevalence of these risk factors is particularly high in the Gulf region, better diagnosis and management of type 2 diabetes (T2D) and hypertension has the potential to dramatically reduce adverse cardiovascular outcomes for individuals in that part of the world. This article provides a summary of presentations made during the EVIDENT summit, a virtual symposium on Evidence in Diabetes and Hypertension, held in September 2021, including a review of the various guidelines for both T2D and hypertension, as well as recent findings relevant to the safety and efficacy for therapies relating to these conditions. Of relevance to the Gulf region, the risk of hypoglycaemia with sulfonylureas during Ramadan was reviewed. For the management of T2D, sulfonylureas have been a long-standing medication used to achieve glycaemic control; however, differences have emerged between early and later generations, with recent studies suggesting improvements in the safety profiles of late-generation sulfonylureas. For patients with hypertension, incremental therapy changes are recommended to reduce the risk of cardiovascular complications that are associated with increasing blood pressure. For first-line therapy, angiotensin-converting enzyme inhibitors (ACEi), such as perindopril, have been demonstrated to reduce the risk of cardiovascular and all-cause mortality. The addition of calcium channel blockers and diuretics to ACEi has been shown to be effective in patients with poorly controlled hypertension. The different renin-angiotensin-aldosterone system inhibitors are reviewed, and the benefit of combination therapies, including amlodipine and indapamide in patients with difficult-to-control hypertension, is investigated. The benefits of lifestyle modifications for these patients are also discussed, with important clinical considerations that are expected to inform patient management in daily clinical practice.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeafbc6b858ee00023f90ecc0c3a494fTest
https://doi.org/10.1007/s13300-022-01282-4Test

المؤلفون: Alicia McMaster, Jean Claude Mbanya, MG Musa, A Chadli, Aslam Amod, K Naidoo, Hilton M. Kaplan

المصدر: Journal of Endocrinology, Metabolism and Diabetes of South Africa; Vol. 26 No. 3 (2021); 76-81

مصطلحات موضوعية: medicine.medical_specialty, Standard of care, business.industry, Endocrinology, Diabetes and Metabolism, Developing country, Type 2 diabetes, medicine.disease, Endocrinology, Family medicine, Diabetes mellitus, Internal Medicine, Africa, diabetes, macrovascular, microvascular, standard of care, type 2, Medicine, business

الوصف: Diabetes is a major economic burden and has rapidly increased worldwide. Type 2 diabetes, which accounts for 90–95% of cases, has increased particularly in the developing world. Early treatment intensification may decrease the morbidity and mortality of diabetes by lowering the risk of related chronic complications. The majority of patients, however, do not achieve glycaemic targets, and consequently suffer from complications secondary to suboptimal glycaemic control. A large number of epidemiological studies or national registers have been analysed at both country and regional levels, particularly in developed countries, in order to assess the quality of care in patients with diabetes, or to determine compliance with national treatment guidelines. There is a paucity of data from the developing world, particularly in Africa, with regard to the quality of care of people with type 2 diabetes. A better understanding of the missing gaps within current diabetes management is therefore required in order to improve the quality of care of these patients.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87b0736ae33984cc1e41ba5dd3b84d3dTest
https://www.ajol.info/index.php/jemdsa/article/view/233654Test

المؤلفون: A Hariram, Aslam Amod, D Webb, A Kok

المصدر: Journal of Endocrinology, Metabolism and Diabetes of South Africa; Vol. 26 No. 2 (2021); 60-65

مصطلحات موضوعية: medicine.medical_specialty, Observational study, outcomes, real-world evidence, treatment patterns, type 2 diabetes, business.industry, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Diabetes management, Emergency medicine, Cohort, Internal Medicine, medicine, Routine clinical practice, In patient, Disease management (health), business, Baseline (configuration management)

الوصف: Objectives: To describe disease management patterns and associated outcomes in patients with type 2 diabetes initiating a second-line glucose-lowering therapy in routine clinical practice in South Africa. Design: Non-interventional observational study. Setting: General and specialist private practices. Subjects Patients with diabetes initiating second-line glucose-lowering therapy. Outcome measures: Variables collected at baseline and at 6-, 12- and 24-month follow-up visits included sociodemographics, first- and second-line glucose-lowering treatments and other medications, reasons for change in diabetes therapy, HbA1c target set by the attending clinician at the time of change, comorbidities and health-related quality of life (HRQoL). Results: Baseline data were collected for 519 patients (69% female). Mean age was 54.6 years and mean time since initial diagnosis was 7.5 years. Mean HbA1c at baseline was 9.0% and the most common second-line treatment approach was to combine metformin with a sulphonylurea. Median HbA1c and median fasting glucose measurements were marginally lower at 24 months than at baseline (8.0% vs. 8.4%, and 8.5 mmol/l vs. 8.8 mmol/l, respectively). Only approximately 5% of patients had had their diabetes medication changed at any time after the baseline visit. Conclusions: Management of type 2 diabetes mellitus in private practice in South Africa is suboptimal.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db66805fb7b38d4500cad63b5042e4edTest
https://www.ajol.info/index.php/jemdsa/article/view/233609Test

المؤلفون: Adrian Sieberhagen, Khalid Tayeb, Saud Al Sifri, Marina Shestakova, Aslam Amod, Ebtesam Zakaria, Malha Azzouz, Samir Assaad-Khalil, Salah Harb, Rachid Malek, Monira Al Arouj, Abdullah Bennakhi, Ten Olegovna, Bernd Voss, Maysoon Loulou, Zankel Myrga

المصدر: Endocrine Practice. 28:S14

مصطلحات موضوعية: Endocrinology, Endocrinology, Diabetes and Metabolism

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::981b78daf46944e0d12720d01b31f776Test
https://doi.org/10.1016/j.eprac.2022.10.020Test

المؤلفون: Stefan D. Anker, Aslam Amod, Luis M. Ruilope, Gerasimos Filippatos, Amer Joseph, Michel Marre, Bertram Pitt, Charlie Scott, Andrea Lage, Rajiv Agarwal, George L. Bakris, Peter Rossing

المساهمون: IT University of Copenhagen, Indiana University School of Medicine, Indiana University System, Charité Campus Virchow-Klinikum (CVK), National and Kapodistrian University of Athens (NKUA), University of Michigan [Ann Arbor], University of Michigan System, University of KwaZulu-Natal (UKZN), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Bayer Pharma AG [Berlin], The University of Chicago Medicine [Chicago], IT University of Copenhagen (ITU), University of KwaZulu-Natal [Durban, Afrique du Sud] (UKZN), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Gestionnaire, HAL Sorbonne Université 5

المصدر: Rossing, P, Agarwal, R, Anker, S D, Filippatos, G, Pitt, B, Ruilope, L M, Amod, A, Marre, M, Joseph, A, Lage, A, Scott, C, Bakris, G L & the FIDELIO-DKD Investigators 2022, ' Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment : A subgroup analysis from the FIDELIO-DKD trial ', Diabetes, Obesity and Metabolism, vol. 24, no. 1, pp. 125-134 . https://doi.org/10.1111/dom.14558Test
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, Wiley, 2021, ⟨10.1111/dom.14558⟩

مصطلحات موضوعية: medicine.medical_specialty, Finerenone, Endocrinology, Diabetes and Metabolism, Enfermedad cardiovascular, glucagon-like peptide-1 receptor agonist, Urology, Renal function, Subgroup analysis, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, Tratamiento médico, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Myocardial infarction, mineralocorticoid receptor antagonist, Naphthyridines, Renal Insufficiency, Chronic, finerenone, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Fallo renal crónico, business.industry, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, 3. Good health, Diabetes mellitus tipo 2, Sistema endocrino, Diabetes Mellitus, Type 2, Heart failure, type 2 diabetes, business, chronic kidney disease, Glomerular Filtration Rate, Kidney disease

الوصف: Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO-DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on the treatment effect of finerenone. Materials and Methods Patients with type 2 diabetes, urine albumin-to-creatinine ratio (UACR) 30-5000 mg/g and estimated glomerular filtration rate 25

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e510c2d9fbacfc8d63bdfb21efa8263bTest
https://curis.ku.dk/ws/files/290250428/Efficacy_and_safety_of_finerenone_in_patients_with_chronic_kidney_disease_and_type_2_diabetes_by_GLP_1RA_treatment.pdfTest

المؤلفون: Viswanathan Mohan, Mohamed Hassanein, Kamlesh Khunti, Aslam Amod, Moon-Kyu Lee

المصدر: Diabetes Therapy

مصطلحات موضوعية: medicine.medical_specialty, medicine.drug_class, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Review, Type 2 diabetes, Guidelines, 030204 cardiovascular system & hematology, Maturity onset diabetes of the young, Glibenclamide, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Gliclazide MR, Gliclazide, Sulfonylureas, Ramadan, business.industry, nutritional and metabolic diseases, Type 2 Diabetes Mellitus, medicine.disease, Sulfonylurea, Metformin, business, medicine.drug

الوصف: In patients with type 2 diabetes mellitus (T2DM) who require additional glucose-lowering on top of first-line metformin monotherapy, sulfonylureas are the most common choice for second-line therapy followed by dipeptidyl peptidase inhibitors (DPP-4i). This article summarises presentations at a symposium entitled "Real-World Evidence and New Perspectives with Gliclazide MR" held at the International Diabetes Federation Congress in Busan, South Korea on 4 December 2019. Although guideline recommendations vary between countries, the guidelines with the highest quality ratings include sulfonylureas as one of the preferred choices as second-line therapy for T2DM. Data from randomised controlled trials (RCTs) have consistently demonstrated that sulfonylureas are effective glucose-lowering agents and that the risk of severe hypoglycaemia with these agents is low. In addition, both RCTs and real-world observational studies have shown no increased risk of mortality or cardiovascular disease with the use of newer-generation sulfonylureas compared with other classes of glucose-lowering treatments. However, differences between sulfonylureas do exist, with gliclazide being associated with a significantly lower risk of mortality or cardiovascular mortality compared with glibenclamide, as well as the lowest incidence of severe hypoglycaemia compared with other agents in this class. Recent real-world studies into the effectiveness and safety of gliclazide appear to confirm these findings, and publication of new data from these studies in patients with T2DM in the UK, and in Muslim patients who are fasting during Ramadan, are awaited with interest. Another study being undertaken with gliclazide is a pan-India study in patients with maturity-onset diabetes of the young (MODY) subtypes 1, 3 and 12. Patients with these MODY subtypes respond particularly well to sulfonylurea treatment, and sulfonylureas are the first-line agents of choice in these patients. These new and ongoing studies will add to the cumulative data on the efficacy and safety of certain sulfonylureas in patients with diabetes.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4155b95748897535f18768e5bf97929Test
https://doi.org/10.1007/s13300-020-00833-xTest

المؤلفون: Kamlesh Khunti, Moon-Kyu Lee, Viswanathan Mohan, Aslam Amod, Mohamed Hassanein

المصدر: Diabetes Therapy

مصطلحات موضوعية: medicine.medical_specialty, Editorial, business.industry, Endocrinology, Diabetes and Metabolism, Diabetes mellitus, Internal Medicine, MEDLINE, Medicine, Type 2 diabetes, business, Intensive care medicine, medicine.disease, Real world evidence

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::420922ecb8fb20e24cc464cf19e84224Test
http://europepmc.org/articles/PMC7415044Test

المؤلفون: Aslam Amod

المصدر: Diabetes Therapy

مصطلحات موضوعية: medicine.medical_specialty, Type 2 diabetes mellitus, business.industry, Endocrinology, Diabetes and Metabolism, media_common.quotation_subject, nutritional and metabolic diseases, 030209 endocrinology & metabolism, Review, 030204 cardiovascular system & hematology, Consensus report, 03 medical and health sciences, Presentation, Critical appraisal, 0302 clinical medicine, Family medicine, Internal Medicine, Medicine, Evidence-based guidelines, Sulfonylureas, business, media_common

الوصف: This review describes a presentation at a recent symposium entitled “SUs in the treatment of T2DM: a fresh look and new insights” on Wednesday September 18, 2019 at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. It examines the current role of sulfonylureas (SUs) in the management of type 2 diabetes mellitus (T2DM) and gives the author’s personal perspective of how this therapeutic class has performed in both local and international guidelines. The place of SUs within current guidelines is highlighted, and a critical appraisal of the reasons for the differences between guidelines given. Finally, comparison of evidence-based guidelines and consensus reports is discussed.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc12485cc9f299d418ff69b93579050eTest
https://doi.org/10.1007/s13300-020-00811-3Test